HOUSTON--(BUSINESS WIRE)--Alulim Pharma, Inc., an aerosol therapeutics company, emerged today with a seasoned management team and a robust portfolio of pre-clinical and clinical data, along with existing intellectual property protection. Alulim’s proven platform technology allows drugs, both water-soluble and insoluble, to be uniquely and safely deposited throughout the respiratory tract, in contrast to newer and unproven platforms. The key benefits of decreased toxicity and more rapid-targeted drug distribution to treat cancers, asthma, organ transplantation and various infections have already been demonstrated.
